Articles with keyword immunotherapy

IMMUNOTHERAPY (N.M. Volkov)

cancer immunotherapy, effectiveness, toxicity, hyperprogression, predictive biomarkers.

CANCER IMMUNOTHERAPY (N.M. Volkov)

cancer immunotherapy, immune check-point inhibitors, chimeric antigen receptor, clinical trials.

Cell-based anticancer immunotherapy methods (N.M. Volkov)

сell-based immunotherapy, adoptive therapy, dendritic cell, vaccine, T-lymphocyte, natural killer, cancer

A history of cancer immunotherapy (V.M. Moiseyenko, N.M. Volkov)

anticancer immunity, cancer immunotherapy, history, vaccines, cytokines, adoptive therapy, antibody, immune check-point inhibitor

PROSPECTS FOR IMMUNOTHERAPY OF VIRUS-ASSOCIATED TUMORS (I.V. Samoilenko, Ya.I. Zhulikov, L.V. Demidov)

virus-associated malignancies, immunotherapy, CAR-T, engineered TCR, anti-PD1.

FUTURE OF SYSTEMIC THERAPY IN ONCOUROLOGY: TARGETED AND IMMUNOTHERAPY (F.V. Moiseenko)

immunotherapy, targeted therapy, checkpoint inhibitors, urothelial cancer, renal cell cancer.

Immunotherapy is based on cytokines (IL-1, IL-2, FNO, CSF, IFN) (V.A. Chubenko)

immune system, cytokines, interleukins, interferons, colony stimulating agents, microenvironment, strategies of the immunotherapy

What has changed in clinical oncology practice In 2019? (M.Y. Fedyanin)

cancer, chemotherapy, immunotherapy, targeted therapy.

Microbiome and its role in oncology (F.V. Moiseenko, S.V. Ugai, N.M. Volkov)

drug therapy, cancer, microbiome, immunotherapy.

2018 NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE (F.V. Moiseenko, V.M. Moiseyenko)

cancer, treatment, immunotherapy, checkpoint inhibitors.

2016: advances in medical oncology (V.A. Chubenko)

immunotherapy, target therapy, overall survival, treatment guidelines

Colorect al molecular subtypes – progress or deadlock ? (M.Yu. Fedyanin, E.O. Ignatova, А.А. Tryakin)

colorectal cancer, molecular subtypes, immunotherapy, targeted therapy.

Immune checkpoint inhibitors in the treatment of cervical cancer: literature review (O.A. Pardabekova)

cervical cancer, immunotherapy, immune checkpoint inhibitors, pd-1,

Myeloid-derived suppressor cells: origin, phenotype, functions, mechanisms of interaction with immune cells during tumor growth (T.N. Zabotina, I.O. Panchuk, D.V. Tabakov, E.N. Zakharova)

myeloid suppressor cells, immunosuppression, oncology, immunotherapy, antitumor immunity.

MEDICAL TREATMENT OF TUMORS: WHAT NEED TO KNOW A PRAC TICAL ONCOLOGIST (V.A. Chubenko)

chemotherapy, immunotherapy, target therapy, overall survival, treatment guidelines.

New and promising immune oncology drugs combinations (N.М. Volkov)

malignant tumors, cancer immunotherapy, immune check-point inhibitors, combinations.

2015 main events in drug therapy (F.V. Moiseenko)

immunotherapy, program cell death protein inhibitors, targeted therapy, cancer drug therapy

Percutaneous energy-based tumor ablation: principles, technologies, results (P.V. Balakhnin, A.S. Shmelev, E.G. Shachinov)

radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation, laser ablation, ultrasound ablation, cancer immunotherapy, interventional radiology

Fundamental oncology in 2015: a review of the most interesting discoveries (E.N. Imyanitov)

сancer immunotherapy, fundamental oncology, microsatellite instability, acquired cancer resistance, circulating tumor DNA, cancer hormonotherapy, KRAS mutation

RADIATION ONCOLOGY: NOTA BENE FOR PRAC TICING ONCOLOGISTS (N.V. Dengina, T.V. Mitin)

radiation oncology, multidisciplinary team, chemoradiotherapy, trimodality treatment, radiotherapy effect evaluation, combination of radiotherapy and immunotherapy.

Urgent issues of drug therapy and possible solutions (E.V. Karabina)

precision oncology, effectiveness of immunotherapy of malignant tumors, effectiveness of chemotherapy of malignant tumors, recovery of patients with advanced cancer.

Efficacy of immune checkpoints inhibitors in the treatment of solid tumors (A.A. Rumyantsev, S.A. Tjulandin)

drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy